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Letters to the Editor
MISLEADING ANALYSES
SIR.-A recent paper by Harris et al. (1978)
(Br. J. Cancer, 37, 282) includes ananal.s-sis of
the survival after relapse of 29 relapsed
patients withacutemyeloidleukaemia (AML).
Nine of these, previously chosen at random,
were to receive chemotherapy while in remis-
sion (I + C) while 20 were not (I). As might be
expected in such a small study, there was no
significant difference between the post-relapse
survival experience of these 2 groups as
assessed by conventional statistical methods.
When the trial was reported 4/9 (44%) ofthe
I + C's remained alive, as against only 3/20
(15%) of the I's. Fig. 1 gives the life-table
estimates ofthe survival probabilities in these
groups; the long flat region in the life-table
for the 9 I + C's makes their overall survival
look better, but with groups as small as this
such apparent "plateaus" are often without
real meaning. The logrank chi-square com-
paring the 2groupsisonly 0 3 (P = 0 6), sothe
apparent superiority ofthe I + C's is the sort
of difference which can easily arise just by
chance between groups given equivalent
treatments.
Usually, this would be the end of the
description of such results, but having done
these conventional life-table and logrank
analyses, and having concluded that "there
was no significant difference in overall
survival after relapse", Harris et al. then re-
analysed these same data using a different,
and potentially very misleading, method of
statistical analysis. Their non-standard re-
analysis actually gives the inverted impres-
sion that the I + C's have fared significantly
(P < 0-01) worse than the I's. This is so
completely contrary to the non-significant
superiority of I + C indicated by standard
statistical methods that it is perhaps worth-
while seeing where Harris et al.'s second
analysis departs from standard practice.
Fundamentally, the trouble is that they
have examined the distribution of times of
death only of those who died. This would be
satisfactory only if it were thought that
treatment might affect when those who die
before the trial is reported will do so, but
could not possibly affect who died before the
trial was reported, and although AML is a
heterogeneous entity, these assumptions are
too specific (and study-dependent) to be
plausible. Otherwise, the average time of
death ofthose who diedisadangerousstatistic
to use, because low values of it can result
either from a bad treatment, which causes lots
of early deaths, or from a good treatment,
which prevents lots oflate deaths (so that the
average of those death times which remain is
low). Thus, we cannot tell whether a low
average value is bad or good. In their trial,
about half of each group die in the first few
months (see Fig. 1), but after that no more
I + C'sdie, while most oftheremaining I's do
die later. Thus, the I + C's have fared a little
better than the I's, as is correctly suggested
by the standard life-tables in Fig. 1. However,
the average time of death of the 5/9 group
I + C patients who died is 146 days post-
relapse (because there were no late deaths) as
against 291 for the 17/20 group I patients
u'ho died.
This second analysis could mislead the
average reader into believing that there is
highly significant (P < 0-01) evidence that
chemotherapy worsens post-relapse survival.
The results section ends thus:
"Although there was no significant diff-
erence in average survival after relapse,
including living patients..., the average
times between first relapse and death
(were) 290-7 ... and 145-6 ... (Fig. 2).
This difference is highly significant (P <
0-01) although this method ofanalysis may
be open to criticism (R. Peto, personal
communication)."
With apologies, I am writing this letter
because, if the analysis is to be publicly
available, so should the criticisms of it. I
reproduce their Fig. 2 (the original legend to
which incorrectly described it as a life-table
andrepeated theP <0.01 claim); comparison
of it with the standard life-table analysis in
Fig. 1 makes clear the errors ofinterpretation
which could arise.
Other serious difficulties of interpretation
could arise from the other non-standardLETTERS TO THE EDITOR
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FIG. 1. Graph from data in Harris et al. (1978), showing standard life-table estimates of the
probability of survival at various times after first relapse of Trial II patients in groups I (circles)
and I + C (squares).
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FIG. 2.-Graph reproduced from Harris et al. (1978), for the same patients as in Fig. 1, "Showing
survival after relapse for patients who died (excluding long survivors) (P < 0-01)".
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statistical methods that have been devised
(Zuhrie (1978) presented trends with time in
estimated median survival at the last MRC
Leukaemia Reviewmeeting) fortheanalysisof
survivorship in the series of studies from
which the above example was drawn. I am
concerned that correct statistical methodology
should be applied to these data, as they
probably represent the largest immuno-
therapy study at any one British hospital.
When analysing survival data from clinical
trials, it is usually unwise to depart from the
standard statistical methods of logrank P-
values and Kaplan-Meier life-tables (as
described, for example, in Br. J. Cancer
(1977) 35, 1) unless expert statistical guidance
is available to avoid misleading inferences
being drawn. The accepted definition of the
"logrank" and "life-table" methods does not
allow survivors to be ignored.
18 July 1978
R. PETO
Department of the Regius
Professor of Medicine,
Radcliffe Infirmary,
Oxford.
SIR.-We have read Mr Peto's letter and
his earlier comments on the manuscript
of our paper (Harris etal. (1978) Br.J. Cancer,
37, 282), which had led to its extensive
revision. Logrank analysis as recommended
by Peto et al. (1977) (Br. J. Cancer, 35, 1) has
been used throughout the paper, and also for
the data used in the lecture given by one of
us (SRZ) at the 1978 MRC Leukaemia
Review meeting. Mr Peto's objections are to
our additional analyses, notably ofrelapse-to-
death times in Manchester Trial 2. These were
acknowledged in our paper, and the data were
made available in full in the appendix.
In view of Mr Peto's comments, it is worth
reiterating our reasons for analysing "re-
lapse-to-death" separately, even though stati-
stical opinions are divided. Essentially, this
eliminated from the analysis those patients
whose atypically long survival might be due
largely to factors other than treatment. We
(Freeman et al. (1973) Br. Med. J., iv, 571;
Harris et al. (1978) Br. J. Canicer, 37, 282)
have reported that the Manchester AML
Immunotherapy Trials have been associated
with unusually easy induction of second and
subsequent remissions, so that in contrast to
experience in other trials, survival following
first relapse is an important part of the
natural history of AML in Manchester.
Secondly, we and others (reviewed by
Harris et al., (1978) Br. Med. Bull. in press)
have observed that in patients with AML
the probability of entering remission and of
prolonged survival are associated with HLA-
type. Consequently, the "tails" or plateaux
of AML survival curves include an excess of
patients with resistance genes related to
HLA. AML patients at the onset of their
disease thus make up a heterogeneous
population, some sub-sets of which are more
likely to become long survivors than others.
These observations expose the fundamental
fallacies of randomized trials of indifferent
treatment protocols for rare fatal diseases like
AML. Inevitably, small numbers mean that
each treatment arm will contain different
proportions of patients with inherently good
or bad prognosis in relation to the form of
treatment that they receive. Genetically
determined differences in patients' resistance
may greatly exceed the minor differences to
be expected from poor treatment protocols.
The otherwise excellent logrank method
advocated by Peto cannot compensate for
unrecognizedpatientheterogeneity,andfuture
trials should be organized to test the hypo-
thesis that treatment should be tailored to
suit genotype. Finally, statistical nuance
may become much less important when
adequate treatment for AML is available.
28 July 1978
R. HARRIS
S. R. ZUHRIE
Department of Medical Genetics,
St Mary's Hospital,
Manchester.